Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared

Two names appear more frequently in American medicine cabinets than almost any others: Pfizer and Johnson & Johnson. Both are among the largest pharmaceutical and healthcare companies in the world. Both have shaped the consumer healthcare market for decades. But their strategies, brand portfolios, and business models have diverged sharply over the past few years in ways that have significant implications for the brands consumers use daily.

Pfizer reported revenues of approximately $63.6 billion for fiscal year 2024, a sharp decline from the pandemic-era peak of $100.3 billion in 2022 when COVID-19 vaccine and antiviral revenues dominated. Johnson & Johnson reported revenues of approximately $88.8 billion for fiscal year 2024, reflecting the company's deliberate transformation into a pure-play pharmaceutical and MedTech company following the separation of its consumer health division.

Understanding what each company owns and how those portfolios have shifted helps explain why some of the most trusted brands in your bathroom cabinet are changing hands, and why the two companies increasingly look less alike than they used to.

The Defining Strategic Divergence: Consumer Health

The most important development in understanding both companies in 2025 and 2026 is J&J's separation of its consumer health business.

In May 2023, Johnson & Johnson spun off its consumer health division as an independent public company called Kenvue (NYSE: KVUE). This separation transferred ownership of some of the most recognizable consumer brands in the world out of J&J and into a new, independent entity.

Kenvue now owns: Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, Benadryl, Nicorette, Motrin, Johnson's Baby, Visine, and OGX hair care, among others.

J&J no longer owns these brands. This is one of the most consequential consumer brand separations in recent history and is widely misunderstood. When consumers associate J&J with Tylenol or Band-Aid, they are referencing the pre-2023 corporate structure. As of early 2026, those brands are owned by Kenvue.

Pfizer, by contrast, completed its own consumer health separation in 2019 when it merged its consumer healthcare business with GlaxoSmithKline's consumer division to form Haleon (NYSE: HLN, LSE: HLN), which became a separately traded company in 2022. Pfizer's consumer brands including Advil, Centrum, Caltrate, Preparation H, ChapStick, and Emergen-C are now owned by Haleon, not Pfizer.

Both Pfizer and J&J have therefore exited the consumer health brand business in favor of concentration on pharmaceuticals, vaccines, and medical devices.

What Johnson & Johnson Actually Owns Today

The post-Kenvue Johnson & Johnson is a two-segment company: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and surgical equipment).

Innovative Medicine is J&J's largest segment by revenue, generating approximately $57 billion in 2024. Key brands include:

• [Darzalex](/brands/darzalex) (daratumumab) -- multiple myeloma treatment, one of J&J's highest-revenue drugs globally
• [Tremfya](/brands/tremfya) (guselkumab) -- plaque psoriasis and psoriatic arthritis
• [Stelara](/brands/stelara) (ustekinumab) -- Crohn's disease, ulcerative colitis, psoriasis; facing biosimilar competition from 2023
• [Erleada](/brands/erleada) (apalutamide) -- prostate cancer
• [Spravato](/brands/spravato) (esketamine nasal spray) -- treatment-resistant depression
• [Carvykti](/brands/carvykti) (ciltacabtagene autoleucel) -- CAR-T cell therapy for multiple myeloma
• [Rybrevant](/brands/rybrevant) (amivantamab) -- non-small cell lung cancer

J&J's pharmaceutical pipeline is among the strongest in the industry, with approximately 90 compounds in clinical development across oncology, immunology, neuroscience, cardiovascular, and infectious diseases.

MedTech generates approximately $31 billion in revenue, spanning surgical robotics (the Ottava robotic surgery system in development), orthopedics (DePuy Synthes), electrophysiology, vision care, and wound closure. J&J's MedTech division competes directly with Medtronic, Stryker, and Becton Dickinson across multiple categories.

What Pfizer Actually Owns Today

Pfizer, post-consumer health separation, is a pharmaceutical and vaccine company. The company's revenue composition shifted dramatically: COVID-19 products (Comirnaty vaccine and Paxlovid antiviral) contributed approximately $37 billion in 2022 revenues but contracted sharply as the pandemic phase ended. Pfizer is actively rebuilding its commercial pharmaceutical portfolio through acquisitions and internal pipeline development.

Key Pfizer brands and revenue drivers include:

• [Eliquis](/brands/eliquis) (apixaban, co-marketed with Bristol-Myers Squibb) -- anticoagulant; one of the world's highest-revenue drugs
• [Vyndaqel/Vyndamax](/brands/vyndaqel) (tafamidis) -- transthyretin amyloid cardiomyopathy; a high-growth rare disease franchise
• [Ibrance](/brands/ibrance) (palbociclib) -- HR+/HER2- breast cancer
• [Prevnar family](/brands/prevnar) -- pneumococcal vaccines for children and adults; a cornerstone Pfizer franchise
• [Nurtec ODT](/brands/nurtec) (rimegepant) -- migraine prevention and acute treatment, acquired through Biohaven Pharmaceuticals in 2022
• [Oxbryta](/brands/oxbryta) (voxelotor) -- sickle cell disease (acquired through Global Blood Therapeutics 2022; voluntarily withdrawn from market in 2023 following safety data review)
• [Paxlovid](/brands/paxlovid) (nirmatrelvir/ritonavir) -- oral COVID-19 antiviral; commercial sales ongoing but significantly lower than pandemic peak
• [Comirnaty](/brands/comirnaty) -- mRNA COVID-19 vaccine (developed with BioNTech)

Pfizer's largest acquisition in its history came in December 2023 when it completed the purchase of Seagen for approximately $43 billion. Seagen was a pioneer in antibody-drug conjugate (ADC) cancer therapies, and its pipeline added multiple oncology assets to Pfizer's portfolio including Padcev, Tivdak, Tukysa, and Adcetris.

Acquisition Histories Compared

Both companies are serial acquirers, but their acquisition strategies reflect different priorities.

Pfizer's major acquisitions (recent history):

J&J's major acquisitions (recent history):

Head-to-Head: Therapeutic Area Comparison

Oncology: J&J holds a stronger position in hematological oncology (blood cancers) through Darzalex and Carvykti. Pfizer, following the Seagen acquisition, has become a significant force in solid tumor oncology through ADC therapies. Both companies are investing heavily in the fast-growing cancer treatment market.

Immunology/Inflammation: J&J's immunology franchise (Stelara, Tremfya) is one of the most established in the industry, though Stelara faces biosimilar erosion. Pfizer is rebuilding in this area following pipeline additions through acquisitions.

Cardiovascular/Rare Disease: Pfizer's Vyndaqel/Vyndamax franchise for transthyretin amyloid cardiomyopathy is a high-growth rare disease asset with limited direct competition. J&J's cardiovascular presence is primarily through MedTech (Abiomed heart pumps, electrophysiology devices).

Vaccines: Pfizer's vaccine franchise (Prevnar pneumococcal vaccines, Comirnaty COVID vaccine) is one of the industry's strongest commercial vaccine positions. J&J's COVID vaccine is no longer actively marketed; its vaccine franchise is narrower than Pfizer's.

MedTech: J&J has a dominant MedTech division with no Pfizer equivalent. This is the clearest structural differentiation between the two companies. J&J's surgical robotics, orthopedics, and electrophysiology businesses create revenue streams and competitive moats that purely pharmaceutical Pfizer cannot match.

Financial Scale Comparison (FY2024)

Sources: Company annual reports FY2024. All figures approximate.

What This Means for Consumers

The consumer-facing implications of these structural changes are significant and often misunderstood.

The brands in your medicine cabinet associated with Johnson & Johnson -- Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno -- are now owned by Kenvue, which is an independent public company. J&J retains no ownership of these brands following the 2023 Kenvue spin-off.

Similarly, Pfizer-associated consumer brands including Advil, Centrum, ChapStick, and Emergen-C are now owned by Haleon, a separately traded company formed through the merger of Pfizer's and GSK's consumer health businesses.

Both pharmaceutical giants have therefore positioned themselves as pure healthcare companies focused on prescription drugs, vaccines, and in J&J's case medical devices. The consumer brands that made both companies household names now belong to different corporate entities.

For consumers tracking healthcare brand ownership, the post-separation landscape requires understanding three distinct corporate entities in each case: the pharmaceutical parent (Pfizer or J&J), the consumer spin-off (Haleon or Kenvue), and any continuing licensing or trademark arrangements.

FAQ

Does J&J still own Tylenol? No. Tylenol is now owned by Kenvue, Inc. (NYSE: KVUE), an independent consumer health company that was spun off from Johnson & Johnson in May 2023. The spin-off transferred all of J&J's consumer health brands, including Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, and others, to Kenvue. J&J retained its pharmaceutical and MedTech businesses.

Does Pfizer still own Advil? No. Advil is now owned by Haleon plc (NYSE: HLN, LSE: HLN), a consumer healthcare company formed through the combination of Pfizer's and GlaxoSmithKline's consumer health businesses. Haleon was listed as an independent company in July 2022. Pfizer sold its remaining stake in Haleon progressively following the listing.

Which company is bigger, Pfizer or J&J? By total revenue, Johnson & Johnson generated approximately $88.8 billion in fiscal year 2024 compared to Pfizer's approximately $63.6 billion. By market capitalization as of early 2026, J&J is significantly larger. However, in pharmaceutical-only revenue, the two companies are roughly comparable, as J&J's advantage is largely attributable to its MedTech division.

What was Pfizer's most recent major acquisition? Pfizer's most recent transformative acquisition was Seagen, completed in December 2023 for approximately $43 billion. Seagen's antibody-drug conjugate cancer therapy platform significantly expanded Pfizer's oncology portfolio and pipeline.

Why did J&J separate its consumer health business? J&J management cited the desire to allow both businesses to pursue distinct strategies with appropriate capital allocation and investor bases. The consumer health business operates at different growth rates, margin profiles, and competitive dynamics than pharmaceuticals and MedTech. Separation also allowed J&J to isolate ongoing talc-related litigation from its pharmaceutical and MedTech operations. The resulting Kenvue is now one of the world's largest consumer health companies.

Explore Related Content

• Pfizer company profile -- Full pipeline, ownership, and corporate structure
• Johnson & Johnson company profile -- Post-Kenvue structure and brand portfolio
• Advil -- Now owned by Haleon, formerly Pfizer consumer health
• Tylenol -- Now owned by Kenvue, formerly J&J consumer health
• Band-Aid -- Now owned by Kenvue, formerly J&J consumer health
• Why Big Pharma Keeps Buying Smaller Drug Brands

Sources

1. Pfizer Annual Report FY2024 -- https://investors.pfizer.com/financial-reports/annual-reports/ 2. Johnson & Johnson Annual Report FY2024 -- https://investor.jnj.com/annual-reports 3. Kenvue Inc. Annual Report FY2024 -- https://ir.kenvue.com/financial-information/annual-reports 4. Haleon plc Annual Report FY2024 -- https://www.haleon.com/investors/results-and-reports/ 5. U.S. Securities and Exchange Commission: Kenvue Form 10-K -- https://www.sec.gov/cgi-bin/browse-edgar 6. Bloomberg Intelligence: Pharmaceutical Sector Analysis 2025-2026 -- https://www.bloomberg.com

All brand ownership data verified through WhoBrands.com research methodology. Last updated: March 2026.